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It is well appreciated that organ-specific autoimmune
diseases run in families, but that within a family one mem-
ber may have type 1 diabetes, another autoimmune thyroid
disease, and another multiple sclerosis (1). What causes
clustering of different autoimmune diseases along genetic
lines, and what logic causes the immune system to take aim
at different organ targets? In this issue, Salomon et al. make
the paradoxical finding that interference with a single co-
stimulatory molecule, B7-2, shifts the aim of autoimmunity
 
in the NOD mouse strain away from the pancreatic islet 
 
 
 
cell and onto the peripheral nerves (2). The finding adds an
important molecular clue to the pathogenesis of organ-spe-
cific autoimmune disease, and illustrates the caution that
will be needed as new immunological interventions are ap-
plied in the clinic.
 
The inheritance of susceptibility to organ-specific au-
toimmunity is extraordinarily complex. Particular haplo-
types of the major histocompatibility complex, such as
 
HLA-DR3-DQB1
 
*
 
0201, are strongly associated with hu-
man susceptibility to multiple organ-specific autoimmune
disorders (3). HLA-type nevertheless accounts for only a
fraction of inherited susceptibility, and heterozygosity for
different HLA alleles can either raise or lower the risk. Inde-
pendent of HLA-type, mutations in a non-MHC gene,
AIRE, cause a Mendelian syndrome, APECED, character-
ized by autoimmune manifestations ranging from Addison’s,
thyroid, and parathyroid disease to type 1 diabetes (4, 5).
The AIRE gene product appears to be a nucleic acid bind-
ing protein present in some thymic epithelial and dendritic
cells. Its connection to organ-specific autoimmunity can
only be speculated, perhaps related to presentation of organ
specific antigens for tolerance induction in the thymus.
The unpredictable interactions between MHC and non-
MHC genetic loci have been most clearly illuminated by
the genetic analysis of organ-specific autoimmunity in the
NOD mouse, where it has been possible to create numer-
ous congenic substrains differing at one or more of the 20
or so loci currently shown to contribute to susceptibility
(6). The NOD mouse is an inbred strain derived in Japan
from a mixture of outbred strains (7). A high proportion of
NOD mice spontaneously develop type 1 diabetes due to
destruction of pancreatic islets by T cells. NOD carries a
 
unique MHC class II allele, I-A
 
g7
 
, which makes a major
contribution to diabetes susceptibility (Table I). The I-A
 
g7
 
protein shares a unique amino acid residue in its peptide-
binding cleft with human diabetes–susceptible HLA-DQ
chains. The NOD H-2 haplotype is not sufficient for dia-
betes, however, because when it is placed onto a different
strain background, congenic B6.H-2
 
g7
 
 mice, there is no in-
sulitis or diabetes (6). Strikingly, when a NOD congenic
substrain, NOD.H-2
 
h4
 
, was produced that retained all of
the non-MHC NOD genes but substituted the MHC re-
gion with another MHC haplotype, the congenic animals
were now protected from insulitis and diabetes but became
susceptible to spontaneous autoimmune thyroiditis (8–10).
This observation led to the idea that there was a general
susceptibility to organ-specific autoimmune disease in
NOD mice encoded outside of the MHC—an immuno-
logical gun with a faulty trigger—and that changes in the
way particular antigens were presented simply pointed the
gun at different target antigens and organs (6).
The Salomon results here document a similar shift from
diabetes to autoimmune peripheral neuropathy, precipi-
tated not by a change in the MHC haplotype but by a de-
fined genetic lesion in a single T cell costimulatory ligand,
B7-2 (CD86) (2).
 
Immunogenic Role of B7 Ligands.
 
B7-2 and B7-1
(CD80) are ligands for one of the best characterized T cell
costimulatory receptors, CD28, and for the related inhibi-
tory receptor on T cells, cytotoxic T lymphocyte antigen
(CTLA)-4 (CD152). An important immunogenic role of
B7 ligands for in vivo immune responses has been clearly
shown by treating mice, primates, and humans with block-
ing agents such as anti-B7 mAbs or CTLA-4Ig and show-
ing interference with immune responses to immunization
or transplants (11). Similarly, B7-1–deficient mice showed
a 70% reduction in the stimulation of allogenic mixed lym-
phocyte reactions (12). Immune responses were also im-
paired in B7-2–deficient mice, as no germinal centers were
formed, and antibody isotype switching was reduced upon
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injection of antigen in vivo (13). Surprisingly, in the B7-1/
B7-2 double knockout mice, the phenotype was similar to
that observed in B7-2–deficient mice (13). However, if an-
tigen was injected with adjuvant, then immune responses
in B7-2–deficient mice appeared normal, whereas those in
the double knockout were still impaired. These results sug-
gest that B7-1 and B7-2 have partially overlapping immu-
nogenic roles, whereby an increase in B7-1 expression me-
diated by adjuvant can substitute for B7-2.
CD28 itself has a clearly established immunogenic role,
as CD28-deficient mice have impaired responses to lectins,
reduced T helper activity, and decreased isotype switching
(14). Immune clearance of potently immunogenic antigens,
such as replicating lymphocytic choriomeningitis virus, is
normal. The ability to mobilize effective immune responses
in B7 or CD28 null mice is presumably explained by the
fact that other costimulatory receptor-ligand pairs such as
CD40/CD40L can substitute for delivering immunogenic
costimuli to T cells.
 
Tolerogenic Role of B7 Ligands.
 
Paradoxically, B7-1, B7-2,
and CD28 have also been shown to serve tolerogenic
roles. When a targeted deficiency of B7-1 is backcrossed to
the NOD strain background, this exacerbated the develop-
ment of spontaneous diabetes rather than suppressing the
autoimmune response as might be expected (11). Similar
exacerbation of autoimmune diabetes occurred in NOD
mice carrying a null mutation in CD28 or a double-defi-
ciency of B7-1 and B7-2 (15, 16). In the article by
Salomon et al. lack of B7-2 in NOD mice results in au-
 
toimmune neuropathy (2). Therefore, in the context of
spontaneous autoimmunity in NOD mice, B7-1, B7-2,
and CD28 all appear to be more important for a tolero-
genic function than for immunogenicity.
 
Possible Explanations for Tolerogenic Roles of B7.
 
Immu-
nology—from its origins in vaccinology—is preoccupied
with the responses made to acute stimulation with foreign
antigens. In this context, we assume that occurrence of im-
mune responses relate to the strength of an inductive stim-
ulus, rather than to weakening of a repressive stimulus.
Consequently, it is natural to try to explain the exacerba-
tion of autoimmunity in B7-deficient NOD mice by draw-
ing on the role of these molecules as differentially inductive
stimuli for Th1 and Th2 cytokine responses to immuno-
genic foreign antigens. It is nevertheless very difficult to
explain exacerbation of autoimmunity in this way. Because
B7-2 is suggested to be selectively needed for production
of Th2 cytokines, and Th2 cytokines can prevent diabetes
and inflammation, it might be expected that loss of B7-2
would exacerbate diabetes; yet in NOD mice the opposite
is observed. Conversely, if B7-1 preferentially promotes
Th1 cytokine production, its absence would be expected to
protect against diabetes, rather than exacerbate the disease.
In the absence of both B7-1 and B7-2, few Th1 and Th2
cytokines are produced to immunogenic foreign antigens,
but this still leads to an exacerbation of the autoimmune di-
abetes response (16). Therefore, Th1 and Th2 biases fail to
provide a simple explanation for how B7 ligands prevent
autoimmune responses.
 
Table I.
 
General Predisposition of NOD Mice to Autoimmunity and Tolerogenic Role of B7 Ligands
 
Gene variant Strain Gross phenotype Suggested explanations Reference
H-2
 
g7
 
 (NOD MHC) NOD Insulitis Defect in tolerance induction
 
7
 
Type I diabetes Aberrant target organ
H-2
 
h4
 
NOD Little insulitis  Increased immunogenic presentation of thyroid autoantigens 8–10
No diabetes Decreased immunogenic presentation of islet autoantigens
Thyroiditis
H-2
 
g7
 
B6 No insulitis Regulation of tolerance is normal 6
No diabetes
CD28
 
 
 
/
 
 
 
NOD Exacerbation of diabetes Failure to induce regulatory CD4
 
 
 
25
 
 
 
 cells 15
Failure to induce CTLA-4-mediated inhibition
Failure to induce Th2 cytokines
B7-1
 
 
 
/
 
 
 
NOD Exacerbation of diabetes Failure to induce CTLA-4-mediated inhibition 11
B7-2
 
 
 
/
 
 
 
NOD Little insulitis Predominant expression of B7-2 in islet APCs 2
No diabetes Predominant expression of B7-1 in neural tissue
Autoimmune polyneuropathy
B7-1/B7-2
 
 
 
/
 
 
 
NOD Exacerbation of diabetes Failure to induce regulatory CD4
 
 
 
25
 
 
 
 cells 16
Failure to induce CTLA-4-mediated inhibition
CD28/CD40L
 
 
 
/
 
 
 
NOD No diabetes A sum of costimulatory pathway are interactive:
blocking both “major” pathways
efficiently prevents T cell activation 11 
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In the context of tolerance to self-antigens, immune re-
sponses must be viewed inversely through the looking
glass. Occurrence of an autoimmune disease may primarily
reflect the weakness of tolerogenic responses to these self-
antigens rather than an enhancement of immunogenic
stimuli. B7 ligands appear to have an important role in co-
stimulating these tolerogenic responses (Fig. 1), so that
their removal might be expected to weaken tolerance and
allow or exacerbate autoimmunity. For example, in the
context of TCR engagement in immature thymocytes, co-
stimulation by CD28 augments induction of thymic dele-
tion (17-19). During peripheral T cell tolerance induced by
anergy to poorly immunogenic antigens, recognition of B7
ligands by CTLA-4 is necessary to inhibit or terminate T
cell activation (20, 21), and mice lacking CTLA-4 develop
lethal T cell hyperactivation (22–24).
In addition to tolerance mediated by cell-intrinsic re-
sponses of deletion and anergy, it has long been speculated
that tolerance might be mediated by regulatory/suppressor
cells that are induced by stimulation with self-antigens in
the thymus. Emerging evidence suggests that self-reactive
CD4 T cells are induced by self-antigen within the thymus
to adopt an anergic and suppressive state characterized phe-
notypically by expression of the low affinity IL-2 receptor
 
 
 
 chain (CD25), low levels of CD45RB, and high CD44
(25). Cells with this phenotype have been shown to be
generated from the thymus and be essential for maintaining
organ-specific tolerance to tissues such as the gastric mu-
cosa, ovary, thyroid gland, and pancreatic islet (26, 27).
 
Costimulation by B7 ligands appears to be important for
the tolerogenic responses conferred by these cells. Fewer
regulatory CD4
 
 
 
CD25
 
 
 
 T cells are found in NOD mice
lacking CD28 or both B7-1 and B7-2, and cells with this
phenotype express CTLA-4 and appear to require this in-
hibitory receptor for their suppressive actions (16, 28, 29).
 
Why Might Loss of a Costimulator Change the Focus of Au-
toimmunity?
 
In the article by Salomon et al., lack of B7-2
in NOD mice releases an autoimmune attack on cells of
the peripheral nervous system (PNS) while at the same
time preventing islet inflammation and 
 
 
 
 cell destruction
(2). The suppression of diabetes cannot easily be explained
by the role of B7-2 as an immunogenic costimulator for
effector T cells. One possibility is to invoke the notion
that immunogenic APCs presenting PNS antigens prima-
rily carry B7-1, while immunogenic APCs with islet anti-
gens are predominantly B7-2 positive (Fig. 2). Salomon et
al. raise the possibility that a compensatory increase in B7-1
expression occurs in APCs from B7-2 knockout mice
(2). Assuming this occurs on APCs presenting PNS anti-
gens, the resulting increase in immunogenic stimulation
could explain the development of autoimmune neurop-
athy. Likewise the loss of B7-2 on immunogenic APCs
bearing islet antigens would explain the suppression of in-
sulitis and diabetes. The same reasoning could explain the
exacerbation of diabetes in B7-1 knockout NOD mice,
where a compensatory increase in B7-2 on immunogenic
islet APCs would increase stimulation of autoimmune ef-
fector T cells. This logic falls down, however, in the
CD28-deficient NOD mice, as diabetes is not suppressed
but exacerbated by eliminating the CD28 receptor for
both B7-1 and B7-2.
As costimulators of tolerogenic responses to self-antigens,
however, it is relatively straightforward to see how this shift
in autoimmune target specificity might come about if one
assumes that different self-antigens are presented by differ-
ent subsets of tolerogenic, as opposed to immunogenic,
APCs in the thymus or periphery (Fig. 2). If the deletion of
PNS-reactive T cells, or the induction of PNS-specific an-
ergic/regulatory cells, depends on APCs with primarily
B7-2 expression, then loss of B7-2 would weaken tolero-
genic responses to PNS antigens, allowing autoimmunity to
develop when placed on an intrinsically autoimmune-sus-
ceptible NOD background. Suppression of diabetes would
need to be explained by predominance of B7-2 on immu-
nogenic APCs in the islet, as has been described (30). By
contrast, if the tolerogenic thymic or peripheral APCs for
islet antigens primarily express B7-1, this would explain the
exacerbation of diabetes in B7-1–deficient NOD mice. To
explain the exacerbation of diabetes caused by elimination
of CD28 in NOD mice, the weakening of tolerogenic co-
stimulation to islet antigens by B7-1 would have to be pro-
posed to result in so great a defect in tolerance that the im-
munogenic stimulation of islet effector T cells can be
achieved by CD28-independent costimulatory pathways.
 
The Underlying Autoimmune Defect in NOD Mice: A Gun
with a Hair Trigger or a Missing Safety Lock?
 
NOD mice
spontaneously develop autoimmune diabetes, and also have
Figure 1. Immunogenic and tolerogenic roles of B7 ligands are context
dependent. B7 ligands promote induction of T cell tolerance when anti-
gens are presented chronically and/or early during thymic development.
In the context of antigens presented as an acute burst—during an immune
response to invading pathogens—B7 ligands play an immunogenic role
promoting T cell expansion and effector functions. 
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lymphocytic infiltrates in the thyroid and salivary glands.
Changing the MHC haplotype switches autoimmunity
from diabetes to thyroiditis (8–10), injecting CFA pro-
motes lupus (31), and removing B7-2 induces polyneurop-
athy. NOD mice thus seem generally predisposed to au-
toimmune diseases. This propensity could equally reflect an
increase in immunogenic stimulation by self antigens—an
immunological hair trigger—or a decrease in tolerogenic
stimulation by self antigens—a missing safety lock.
One faulty trigger could be that the target organ for au-
toimmunity expresses a greater propensity for eliciting and
succumbing to autoimmune inflammation. Higher rates of
apoptosis in epithelial salivary cells have been shown to
occur in NOD.SCID mice than in BALB.SCID (6, 32),
and NOD 
 
 
 
 cells are hypersensitive to oxidative stress (6,
33). Subclinical cell stress or dysplasia could release “dan-
ger signals” that deliver immunogenic rather than tolero-
genic signals to dendritic cells and activate autoreactive
lymphocytes.
A second possibility is that tolerogenic antigen presenta-
tion is globally diminished. The NOD MHC I-A
 
g7 
 
is an
unstable structure. This may reduce self-peptide presenta-
tion to developing thymocytes allowing more autoreactive
effector T cells and/or fewer regulatory cells to reach the
periphery. In addition to the MHC-linked susceptibility,
we recently found that NOD.H-2k congenic haemopoietic
precursors intrinsically reconstitute the thymic and splenic
microenvironment with an excess of immature myeloid-
type dendritic cells relative to B10.H-2k hemopoietic pre-
cursors (unpublished data). These results indicate that non-
MHC NOD genes alter dendritic cell maturation, a critical
APC, and this could weaken the balance of tolerogenic and
immunogenic antigen presentation to T cells.
Finally, an intrinsic defect in reception of tolerogenic
stimuli by T cells, preventing adequate induction of central
or peripheral tolerance could also predispose NOD mice to
autoimmune diseases. For instance, induction of central
tolerance is highly dependent on the induction of thy-
mocyte apoptosis, while peripheral tolerance mechanisms
rely on intracellular T cell signaling. Multiple idd loci are
associated to regions containing genes involved in both of
these processes. Still, finer mapping is required before we
can associate genes to idd susceptibility loci. Recently, we
have found evidence that NOD T cells carry an intrinsic
Figure 2. Models to account
for autoimmunity differences
among congenic NOD mouse
strains. (A) Enhancement of im-
munogenic APCs in draining
lymph nodes or within target or-
gan. MHC II and B7-2 stimulate
T cell reactivity to islet antigens,
and B7-1 enhances autoimmu-
nity to PNS antigens. In this
model, deletion of B7-2 would
suppress diabetes by diminishing
immunogenic stimulation by is-
let antigens, and would trigger
autoimmune neuropathy by a
compensatory increase in B7-1
on immunogenic APCs. Au-
toimmunity is not seen in B7-2
knockout B6 mice due to a less
efficient MHCII allele and ab-
sence of other immunogenic co-
stimuli caused by non-MHC
NOD gene alleles. It is difficult
to explain the enhanced autoim-
munity in NOD.CD28 /  mice
by this model. (B) Diminished
presentation of antigens by
tolerogenic APCs. In this model,
islet and neural antigen presenta-
tion is reduced by NOD MHC
II, diminishing induction of tol-
erant T cells and promoting
diabetes. B7-2 is suggested to be
the predominant molecule on
tolerogenic APCs presenting
neural antigens in the thymus or
peripheral nodes, so that its elim-
ination selectively diminishes
tolerance induction to these anti-
gens. By contrast, B7-1 may be the predominant member on tolerogenic APCs bearing islet antigens, so that diabetes is exaggerated when it is inacti-
vated, or when both costimulators or CD28 are eliminated. For spontaneous autoimmunity to occur, other NOD gene alleles are needed to further
weaken tolerogenic responses at the level of tolerogenic APC numbers and by intrinsically diminishing the T cell response to tolerogenic stimuli. 
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defect which prevents their tolerance induction. Using a
TCR transgenic model, we have shown that thymocyte
deletion of islet-reactive CD4 T cells is intrinsically defec-
tive in NOD.H-2
 
k
 
 thymocytes compared with B10. H-2
 
k
 
thymocytes (unpublished data).
Faulty triggers or safety catches could also lie in the con-
trol of T cell costimulation. Indeed, some costimulatory
molecules are closely linked to diabetes susceptibility (idd)
loci. For instance, CD28, CTLA-4, PD-1, and inducible
costimulator (ICOS) are closely linked to idd5 and IL-2 is
almost certainly idd3. A structural polymorphism has been
confirmed in IL-2 between NOD and B6 strains (34).
These important costimulatory molecules could certainly
play a role in the induction of T cell tolerance.
Thus, a sum of faulty safety catches, diminishing tolero-
genic stimulation, and responses at many different levels,
most probably explains the predisposition of NOD mice to
autoimmune diseases.
 
Implications for Human Clinical Intervention.
 
Just as we
do not yet fully understand the pathogenesis of autoimmu-
nity in NOD mice, we are completely operating in the
dark when it comes to the underlying abnormalities of im-
mune regulation that lead to autoimmune disease in hu-
mans. If the pathogenesis stems from a relative deficiency
of a tolerogenic costimulatory signal, and we block that
signal inadvertently or deliberately, there is a very real pos-
sibility of worsening the patients condition. There are
now many examples of molecules whose function was de-
fined in vitro as immunogenic, but when analyzed in vivo
are also tolerogenic (e.g. Lyn kinase, CD40L, IL-2, and
now CD28/B7) (6, 35). We need careful in vivo charting
of the immunogenic and tolerogenic roles of the mole-
cules targeted for immunosuppression. Then, we need
means to measure these regulatory pathways in patients to
tailor the treatment to correct rather than exacerbate the
underlying deficit.
In short, understanding and predicting the role of co-
stimulatory ligands in the development of autoimmune dis-
eases seems more complex then initially believed. We must
carefully understand the role of each costimulatory ligand
before we can predict outcomes of blocking such ligands
for prevention of autoimmune diseases.
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